RecruitingNot ApplicableNCT07093463

Colon-delivered Riboflavin and Gut Microbiota Composition

The Benefit of Colon-delivered Riboflavin (Riboflavin-cd) vs. Conventional Riboflavin on Gut Microbiota Composition and Metabolic Output in Healthy Aging Subjects - a Pilot Proof of Concept Study

Sponsor

dsm-firmenich Switzerland AG

Enrollment

90 participants

Start Date

Jul 18, 2025

Study Type

INTERVENTIONAL

Conditions

Gut health Microbiome Dysbiosis

Summary

Recent studies suggest B-vitamins such as riboflavin to possess prebiotic-like effects. However, there is still a lack of understanding of the exact host health benefits vs. conventional systemically available vitamin forms. The present study explores the benefit of colon-delivered vitamin B2 vs. conventional vitamin B2 in comparison to placebo in an aging population on gut microbiota and metabolic activity as well as gut health.

Eligibility

Min Age: 50 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Colon-delivered riboflavin, Conventional riboflavin, and others for people with gut health and microbiome dysbiosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.